VBS102 / VelaVigo, Ollin Biosciences - LARVOL DELTA

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model (PRNewswire) - "VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo),...announced its second out-licensing agreement of a first-in-class (FIC) asset to Ollin Biosciences, Inc. ('Ollin'), granting Ollin an exclusive license to develop, manufacture and commercialize VBS-102, a first-in-class bispecific antibody, globally (excluding Greater China). VelaVigo will maintain rights for Greater China. Under the terms of the agreement, VelaVigo will receive an upfront fee and future development, regulatory, and commercial milestone payments in cash and equity, totaling up to approximately $440 million in the aggregate, as well as tiered royalties on sales in Ollin's territory."

Licensing / partnership • Immunology • Inflammation • Thyroid Eye Disease